Results from the multinational, pivotal phase III SUNLIGHT* clinical trial of Lonsurf (trifluridine/tipiracil), alone or in combination with bevacizumab, in refractory metastatic colorectal cancer (mCRC) showed a statistically significant and clinically meaningful improvements in overall survival and progression-free survival for patients with refractory mCRC following disease progression or intolerance on two prior chemotherapy regimens compared to trifluridine/tipiracil alone.
First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.
